Join the club for FREE to access the whole archive and other member benefits.


Company focused on the research and development of mitochondria based therapeutics.

Our company is a first mover and leader in exploring the mitochondrial genome for therapeutically relevant peptides that have the potential to be developed into transformative and commercially successful drugs. These peptides have been conserved by evolutionary biology due to their important roles in sensing and regulating critical biological functions, far beyond the energy production most frequently associated with mitochondria. Our team has discovered more than 100 mitochondrial derived peptides (MDPs) and generated over 1,000 analogs.

Visit website:


CohBar is also referenced in the following:

Age Later: Health Span, Life Span, and the New Science of Longevity


Secrets of the Healthiest, Sharpest Centenarians - by Nir Barzilai

People at CohBar

Joseph Sarret

Chief Executive Officer and Director at CohBar

Steven Engle

Chief Executive Officer & Director, CohBar

CohBar News

Longevity.Technology looks at 12 key companies running age-related disease clinical trials in 2021

Longevity Technology - 25-Feb-2022

Approaches include senotherapeutics, stem cells and mitochondria. Eye disease is a common first target.


Liver-fat content and bodyweight reduction with effective use of CB4211

GlobeNewswire - 10-Aug-2021

Mitochondrial genome used to potentially treat fatty liver and prevent obesity


CohBar's lead candidate may initiate clinical trials in 2022

Longevity Technology - 16-Mar-2021

Mitochondrial-based therapy enters IND to tackle IPF and other fibrotic diseases


From cryonic baths to ozone saunas, to the search of magic pill

Wired - 10-Sep-2019

In 2018 consumers spent $43 billion on anti-ageing products according to Orbis analysis